| 51 |
19855080 | Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. | 2009 Dec 10 |
1 |
| 52 |
19934315 | Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. | 2009 Dec 15 |
1 |
| 53 |
17690698 | CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. | 2008 Feb |
1 |
| 54 |
17349636 | Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. | 2007 Apr 3 |
1 |
| 55 |
17376172 | Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment. | 2007 May |
1 |
| 56 |
17538248 | Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. | 2007 Jun |
1 |
| 57 |
17554385 | The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. | 2007 Aug |
1 |
| 58 |
17717597 | FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. | 2007 Sep |
4 |
| 59 |
18024285 | [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis]. | 2007 Nov |
5 |
| 60 |
16572205 | BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. | 2006 Jun |
1 |
| 61 |
16670264 | A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. | 2006 Sep 1 |
1 |
| 62 |
15345592 | Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. | 2005 Mar 1 |
3 |
| 63 |
15618956 | Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. | 2005 Mar |
1 |
| 64 |
15805265 | p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. | 2005 Apr 1 |
1 |
| 65 |
15815728 | Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. | 2005 Jun |
1 |
| 66 |
15933063 | Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. | 2005 Jun 15 |
1 |
| 67 |
15958710 | Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. | 2005 Jun |
1 |
| 68 |
16015388 | Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. | 2005 Sep |
1 |
| 69 |
16107888 | Chronic myeloid leukemia CD34+ cells have elevated levels of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3) and lack a PtdIns(3,4,5)P3 response to cytokines and chemotactic factors; effects reversed by imatinib. | 2005 Oct |
1 |
| 70 |
16204063 | Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. | 2005 Oct 1 |
1 |
| 71 |
16219536 | Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. | 2005 Oct |
1 |
| 72 |
12969987 | Inhibitory effect of imatinib on normal progenitor cells in vitro. | 2004 Jan 15 |
2 |
| 73 |
14504105 | Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. | 2004 Jan 15 |
2 |
| 74 |
14715630 | Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. | 2004 Jun 15 |
2 |
| 75 |
15124675 | Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. | 2004 |
2 |
| 76 |
11986238 | Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. | 2002 May 15 |
2 |
| 77 |
11746976 | Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. | 2001 Dec |
1 |